Amiloride (MK-870): Epithelial Sodium Channel Inhibitor for Ion and Endocytosis Research

Executive Summary: Amiloride (MK-870) is a selective inhibitor of epithelial sodium channels (ENaC) and urokinase-type plasminogen activator receptors (uPAR), with a defined molecular weight of 229.63 Da and formula C₆H₈ClN₇O (APExBIO). It functions as a PC2 channel blocker, modulating sodium and ion transport in cellular assays. Amiloride's inhibitory effects are well characterized in mechanistic studies of sodium channel signaling and endocytosis, but it does not inhibit clathrin-mediated endocytosis in certain viral models (Wang et al., 2018). The compound is suitable for research use only, is stable at -20°C, and requires prompt solution use to maintain activity (APExBIO). This article clarifies Amiloride's validated uses, misconceptions, and integration into sodium channel and cellular uptake research.

Biological Rationale

Amiloride (MK-870) is an established biochemical reagent for studying sodium channel function and epithelial ion transport. Its pharmacological relevance derives from its ability to inhibit ENaC, a critical channel in epithelial sodium absorption, and uPAR, a receptor involved in cellular signaling, migration, and endocytosis (see comparative mechanistic overview). Sodium channel activity underlies diverse physiological and pathophysiological processes, including fluid homeostasis, cystic fibrosis, and hypertension (application review). Inhibition of these pathways by Amiloride allows researchers to dissect specific ion channel and receptor-mediated effects with high specificity.

Mechanism of Action of Amiloride (MK-870)

Amiloride (MK-870) binds directly to the extracellular domain of ENaC, blocking sodium influx through epithelial membranes. This action results in decreased sodium reabsorption and altered cellular osmotic gradients. The compound also inhibits urokinase-type plasminogen activator receptor (uPAR) signaling, influencing processes such as cellular migration and endocytosis. As a PC2 channel blocker, Amiloride modulates additional ion transport mechanisms, broadening its utility in ion channel studies (APExBIO). The specificity and potency of Amiloride have made it a standard in functional assays addressing sodium channel physiology and pharmacology.

Evidence & Benchmarks

• Amiloride inhibits epithelial sodium channels (ENaC) with nanomolar to micromolar potency in vitro, reducing sodium transport across epithelial tissues (internal benchmark).
• In urokinase receptor signaling assays, Amiloride blocks uPAR-mediated pathways, impacting cell migration and invasion rates in established cell models (internal translational evidence).
• In endocytosis research, Amiloride does not inhibit clathrin-mediated uptake of genotype III grass carp reovirus (GCRV104) in CIK cells, as confirmed by viral entry assays and qPCR quantification (Wang et al., 2018, https://doi.org/10.1186/s12985-018-0993-8).
• Amiloride solution stability is limited; fresh preparations are recommended, as activity declines with prolonged storage at ambient temperatures (APExBIO).
• Compound is validated for mechanistic studies of cystic fibrosis, hypertension, and sodium channel pharmacology under controlled laboratory conditions (application summary).

Applications, Limits & Misconceptions

Amiloride (MK-870) is widely used in:

• Sodium Channel Research: Dissecting ENaC function in epithelial tissues and model cell lines.
• Cellular Endocytosis Modulation: Studying uPAR and PC2-mediated uptake, with precise control of extracellular sodium.
• Disease Modeling: Mechanistic studies in cystic fibrosis and hypertension models.
• Workflow Optimization: Enhancing reproducibility in cell viability, proliferation, and cytotoxicity assays (practical guidance).

This article extends prior application reviews by mapping new evidence from viral entry studies, clarifying that Amiloride is not a universal endocytosis inhibitor—a limitation not addressed in earlier summaries (mechanism article).

Common Pitfalls or Misconceptions

• Amiloride does not inhibit clathrin-mediated endocytosis in all viral or cellular contexts; specifically, it does not block GCRV104 entry in CIK cells (Wang et al., 2018, DOI).
• It is not effective in inhibiting non-ENaC sodium channels or other unrelated ion channels.
• Long-term solution storage at ambient temperature or above -20°C leads to loss of potency (APExBIO).
• Amiloride is for research use only; it is not validated for diagnostic or therapeutic applications.
• It is not a pan-endocytosis inhibitor; specificity is limited to certain receptor pathways (uPAR, PC2).

Workflow Integration & Parameters

• Amiloride (MK-870) is provided as a solid reagent; dissolve in suitable solvent (e.g., DMSO or water) immediately before use (product details).
• Store solid compound at -20°C for long-term stability; avoid freeze-thaw cycles.
• Use freshly prepared solutions for maximum activity; discard any unused solutions after experiments.
• Shipping is performed with Blue Ice for small molecules and Dry Ice for modified nucleotides (APExBIO).
• For sodium channel and endocytosis assays, apply at concentrations determined by preliminary titrations (typically 1–100 μM, depending on system and endpoint).
• The BA2768 kit is compatible with standard ion channel, viability, and endocytosis workflows (product page).

Conclusion & Outlook

Amiloride (MK-870) from APExBIO is a rigorously characterized epithelial sodium channel inhibitor with validated applications in sodium channel and cellular uptake research. It is a benchmark tool for mechanistic studies of ENaC and uPAR pathways, though its effects are context-dependent and do not extend to clathrin-mediated endocytosis in all systems. Researchers should ensure proper storage and use protocols to maintain compound integrity and experimental reproducibility. For a deeper strategic analysis, see the translational insight article, which this article updates by integrating viral entry evidence. For comprehensive usage guidance in the lab, consult the workflow integration guide.